ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Features and Transplant Outcomes in Kidney Transplant Recipients with Renal Cell Carcinoma

C. Baek, H. Kim, S. Park

Asan Medical Center, Seoul, Korea, Republic of

Meeting: 2020 American Transplant Congress

Abstract number: B-209

Keywords: Kidney transplantation, Malignancy

Session Information

Session Name: Poster Session B: PTLD/Malignancies: All Topics

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Previous studies have recommended a 2-5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell carcinoma (RCC) and no delay for incidental early-stage RCC. Data on Asian kidney transplant recipients are unavailable.

*Methods: This is a Korean single-center retrospective study on 35 KT recipients with ESRD and RCC (Figure 1). Patients were classified into two groups: early KT (KT performed within 1 year after nephrectomy for RCC, including KT with simultaneous nephrectomy) and delayed KT (KT performed > 1 year after nephrectomy for RCC). Patient survival, graft survival, and cancer recurrence were compared between both groups.

*Results: There were no statistically significant differences in patient survival (P = 0.388, Figure 2A), graft survival (P = 0.317, Figure 2B), or graft rejection rate (P = 0.207) between the early and delayed KT groups. Additionally, there were no differences in pathological characteristics and RCC stage other than cancer histology: acquired cystic disease-associated RCC (47.4%) was the most common RCC type in the early KT group, whereas clear cell type (66.7%) was the most common RCC type in the delayed KT group. No RCC recurrence was observed.

*Conclusions: Patients with early-stage and asymptomatic RCC do not require a mandatory observational period prior to KT after curative nephrectomy.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Baek C, Kim H, Park S. Clinical Features and Transplant Outcomes in Kidney Transplant Recipients with Renal Cell Carcinoma [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-features-and-transplant-outcomes-in-kidney-transplant-recipients-with-renal-cell-carcinoma/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences